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ABSTRACT
Promoter variations in Toll-like receptor genes (n = 7) and genes encoding pathogen recognition and
virus entry receptors (n = 7) were screened to detect any association with human cytomegalovirus
(hCMV) reactivation and disease in patients following allogeneic stem-cell transplantation. Two single
nucleotide polymorphisms (rs735240, G>A; rs2287886, C>T) in the promoter region of the dendritic cell-
speciﬁc ICAM3-grabbing non-integrin (DC-SIGN) showed a signiﬁcant association with an increased
risk of development of hCMV reactivation and disease. Furthermore, these genetic markers inﬂuenced
the expression levels of DC-SIGN on immature dendritic cells, as well as the infection efﬁciency of
immature dendritic cells by hCMV, as determined by hCMV immediate–early antigen staining.
Screening of patients following allogeneic stem-cell transplantation for the presence of these deﬁned
genetic polymorphisms might help to predict the individual risk of hCMV reactivation and disease.
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INTRODUCTION
Human cytomegalovirus (hCMV) is a ubiquitous
b-herpes virus that interacts with various target
cells during acute and latent infection. hCMV is
one of the most signiﬁcant infectious complica-
tions for allogeneic stem-cell transplantation
(alloSCT) patients [1].
The ability of hCMV to recognise and inﬁltrate
a wide range of cells, including dendritic cells
(DCs), monocytes, macrophages, endothelial
cells, epithelial cells, muscle cells and ﬁbroblasts,
suggests that hCMV makes use of different types
of receptors. During the complex entry path,
hCMV binds initially to heparan sulphate pro-
teoglycans (HSPGs) on the host cell surface [2].
In a subsequent step, stronger connection is
mediated by binding of glycoprotein B, a major
compound of the viral capsid, to one of the
cellular receptors. Several different pathogen
recognition receptors (PRRs) and virus entry
receptors of hCMV have been identiﬁed. Virus
entry receptors comprise the epidermal growth
factor receptor [3], integrins [4,5] and the den-
dritic cell-speciﬁc ICAM3-grabbing non-integrin
(DC-SIGN) [6].
Adaptive, T-cell-mediated immune responses,
as well as the innate immune system, usually
control hCMV infection. In early innate
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immunity, Toll-like receptors (TLRs) play a crit-
ical role by interacting with highly conserved
pathogen-associated molecular patterns [7]. TLR2
has been shown to be activated by hCMV virions
during the entry process, thereby triggering
inﬂammatory cytokine production [8]. With
regard to TLR4, bacterial components, as well as
viral structures, have been detected [9]. TLR3 is a
receptor for double-stranded RNA [10], TLR8 has
been shown to recognise single-stranded RNA
[11], and TLR9 is required for response to unme-
thylated CpG DNA [12].
Single nucleotide polymorphisms (SNPs)
located in regulatory or coding regions are of
special interest, as they may inﬂuence the func-
tions of genes by altering gene expression and ⁄ or
by changing the structure of the corresponding
protein [13]. It has been demonstrated previously
that SNPs in TLR genes are associated with
susceptibility to inﬂammation [14]. However,
SNPs in TLR2 (rs1898830, rs3804099, rs3804100)
and TLR4 (rs2737191, rs5030728, rs1554973) are
not associated with hCMV reactivation or disease
[15]. The present study investigated the associa-
tion between deﬁned SNPs (n = 14) in TLR3,
TLR8, TLR9, EGFR, ITGB3, DC-SIGN and SDC2
(HSPG), and asymptomatic hCMV reactivation
(DNAemia) and disease in patients after alloSCT.
Three different patient groups were compared:
patients with hCMV reactivation; patients with
hCMV disease (as deﬁned by Ljungman et al.
[16]); and patients without hCMV reactivation
(controls).
MATERIALS AND METHODS
Sample collection
Between 1994 and 2003, whole blood samples (5–10 mL),
anticoagulated with EDTA, were collected c. 30 days after
alloSCT from 194 patients suffering from acute myeloid
leukaemia, acute lymphatic leukaemia, myelodysplatic syn-
drome, non-Hodgkin’s lymphoma or severe aplastic anaemia.
The combination of a seronegative donor and a seronegative
recipient was excluded from the analysis. All patients were of
European origin (median age 43 years; range 19–55 years; 54%
males) and fulﬁlled the inclusion criteria described previously
[15]. The study population was split into three groups: (i) 70
patients with hCMV reactivation (43% of whom had received
>2 mg ⁄kg body weight corticosteroids for immunosuppres-
sion); (ii) 59 patients with hCMV disease (81% with
corticosteroid treatment); and (iii) 65 controls (66% with
corticosteroid treatment). The retrospective analysis was
approved by the local ethics committees and was conducted
according to the principles of the Declaration of Helsinki.
DNA was extracted using standard methods based on spin-
column technologies and was frozen at –80C until further
analysis. The deﬁned SNPs rs5743318 (TLR3, 4q35), rs2407992,
rs3747414, rs3764880, rs5744077 (TLR8, Xp22), rs352140 and
rs5743842 (TLR9, 3p21.3) were analysed for 69 patients with
hCMV reactivation, 26 patients with hCMV disease, and 51
patientswithout hCMV reactivation because of limited genomic
DNA yield. The association tests for the markers rs2287886 and
rs735240 of DC-SIGN were based on 40 samples in each group.
SNP analysis
With the exception of the two SNPs in DC-SIGN, speciﬁc
oligonucleotide probes for each genetic marker were designed
(TIB MOLBIOL, Berlin, Germany) (Table S1, see Supplemen-
tary material). SNP analysis was performed using the Light-
Cycler system and the LightCycler FastStart DNA Master
Hybridisation Probes Kit (Roche, Mannheim, Germany). Melt-
ing curve analysis was performed using a temperature
transition rate of 0.1C ⁄ s.
Analysis of the SNPs rs2287886 and rs735240 (DC-SIGN)
was performed by matrix-assisted laser desorption ionisation
mass spectrometry (MALDI-MS) (Autoﬂex; Bruker Daltonics,
Bremen, Germany). PCR products were treated with shrimp
alkaline phosphatase, followed by extension of SNP-speciﬁc
biotinylated primers containing a photocleavable linker (Bio-
TeZ, Berlin, Germany) using TERMIpol polymerase (Solis
BioDyne, Tartu, Estonia). Products were puriﬁed using the
Genostrep 96 Kit (Bruker Daltonics), the primers were cleaved
using UV light, and the mass of the extended oligonucleotides
was determined by MALDI–time of ﬂight (TOF) analysis.
Generation of DCs and DC-SIGN expression analysis
Culture of immature DCs (iDCs) used 100 mL of blood from
ﬁve healthy individuals with either the CA or TG haplotype
across markers rs735240 and rs735240. Each individual was
homozygous for the C, respectively T, allele of marker
rs735240, and the A, respectively G, allele of marker
rs2287886. Isolation of monocytes and differentiation into
iDCs was achieved by stimulation with interleukin (IL)-4
and granulocyte–macrophage colony-stimulating factor as
described previously [17]. After 6 days, the cells were har-
vested and the expression of DC-SIGN was analysed by real-
time PCR subsequent to isolation of total RNA and reverse
transcription [18]. The primers and probes used were:
DC-SIGN F, 5¢-CTGAGGAGCAGAACTTCCTACA; DC-SIGN
R, 5¢-GCAAGATTACATTTGTCGTCGT; DC-SIGN FL, 5¢-TGT-
TGCCCAGCTTCAAGCAGTA; and DC-SIGN LC, 5¢-GGAAC-
AGAGGAGAGCCCAACAAC.
hCMV infection and immunocytochemistry
iDCs were infected with hCMV strain TB40E [17] and stained
for immediate–early (IE) antigens as described previously [19]
with minor modiﬁcations. In brief, the cells were resuspended
in medium containing IL-4 and granulocyte–macrophage
colony-stimulating factor, and then incubated with hCMV
suspension or fresh medium for 2 h at 37C. The cells were
then rinsed and cultured in 240-well plates at a density of
1–1.5 · 106 cells ⁄mL. For determination of infection efﬁciency,
iDCs were collected 24 h after infection, cytocentrifuged on to
glass slides, and ﬁxed with acetone. hCMV IE antigen
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expression was detected by indirect immunoﬂuorescence
staining. The slides were incubated with monoclonal antibody
E13 directed against the non-structural IE proteins IE72 and
IE86 (pUL122 ⁄ 123; Biosoft, Paris, France) in an appropriate
dilution for 1 h at 37C, and then with Cy3-conjugated
goat anti-mouse Ig-Fab2 polyclonal serum (Jackson Immuno
Research, West Grove, PA, USA) in an appropriate dilution
under the same conditions. Nuclei were counterstained with
4¢,6-diamidino-2-phenylindole.
Statistical analysis
Statistical analysis was performed as for a classic case-control
study using the allele-frequency-difference test to test for
single-marker associations. As TLR8 is localised on the
X-chromosome, allele frequencies were determined separately
for each gender. The level of signiﬁcance was set to p <0.01
[20,21]. In order to detect population admixture or genotyping
artefacts, each marker was tested for Hardy–Weinberg equi-
librium in both the case and the control group. To analyse the
impact of the genetic components and clinical risk-factors on
hMCV status, a logistic regression analysis was performed
using SAS v.9.1 (SAS Inc., Cary, NC, USA). The patient groups
with hCMV reactivation and disease were treated as categorical
variables, using the controls as the reference category for the
outcome, whereas the genotypes of the markers rs2287886 and
rs735240 and the clinical risk-factors (graft vs. host reaction,
CD34 selection, corticosteroid treatment >2 mg ⁄ kg body
weight) were treated as explanatory variables. A reduced
model was tested, taking only the main effects into account,
and the correlation matrix of the model was derived to
highlight the relationship between the genetic and clinical
factors.
RESULTS
Following alloSCT, the patient call rate (i.e., the
percentage of DNA samples that could be anal-
ysed) using the LightCycler assay (97.3%) and
MALDI-MS (93.3%) were within tolerable ranges.
No signiﬁcant association (p <0.01) between
genetic markers in TLR8, TLR9, EGFR, ITGB3
and SDC2 and hCMV reactivation or disease was
revealed (Table 1). Four markers were revealed to
be monomorphic, i.e., TLR3 (rs5743318), TLR8
(rs5744077), TLR9 (rs5743842) and ITGB3 (rs5921).
However, if the level of signiﬁcance was set to
p <0.05, association analysis for TLR8 and SDC2
revealed that the frequencies of three deﬁned
alleles were increased in patients with hCMV
reactivation ⁄disease. Thus, rs3764880 (TLR8) was
associated with hCMV reactivation (p 0.050), and
rs3747414 (TLR8) and rs1042381 (SDC2) were
associated with hCMV disease (p 0.039 and
p 0.037, respectively).
Table 1. Association between genetic polymorphisms in TLR8, TLR9, DC-SIGN, EGFR, ITGB3 and SDC2 and human
cytomegalovirus (hCMV) reactivation and disease
Gene
dbSNP
number
Nucleotide
positiona Allele Controlb Reactivation Disease
p values
Control vs.
reactivation
Control vs.
disease
Reactivation
vs. disease
TLR8c (Xp22) rs2407992 10 608 C ⁄G C ⁄C 11 18 6 $: 0.912 $: 0.654 $: 0.394
C ⁄G 11 9 4 #: 0.688 #: 0.425 #: 0.174
G ⁄G 28 39 16
rs3747414 10 908 A ⁄C A ⁄A 9 17 3 $: 0.474 $: 0.473 $: 0.719
A ⁄C 7 8 4 #: 0.090 #: 0.608 #: 0.039
C ⁄C 34 44 19
rs3764880 )3679 A ⁄G A ⁄A 38 48 19 $: 0.523 $: 0.884 $: 0.811
A ⁄G 9 5 4 #: 0.050 #: 0.215 #: 0.419
G ⁄G 4 14 3
TLR9 (3p21.3) rs352140 1464 C ⁄T C ⁄C 12 24 4 0.515 0.411 0.068
C ⁄T 24 18 12
T ⁄T 15 17 9
DC-SIGN (19p13) rs2287886 )139 C ⁄T C ⁄C 17 11 24 0.197 0.087 0.003
C ⁄T 18 21 12
T ⁄T 4 6 2
rs735240 )939 A ⁄G A ⁄A 13 3 8 0.010 0.034 0.598
A ⁄G 16 19 16
G ⁄G 7 12 15
EGFR (7p21) rs11543848 142 285 A ⁄G A ⁄A 3 5 3 0.757 0.690 0.918
A ⁄G 17 18 19
G ⁄G 35 39 32
rs10251977 162 093 A ⁄G A ⁄A 26 18 23 0.996 0.974 0.971
A ⁄G 22 28 19
G ⁄G 11 5 10
ITGB3 (17q21.32) rs12709459 37 110 A ⁄C A ⁄A 27 21 25 0.066 0.892 0.055
A ⁄C 28 27 25
C ⁄C 7 15 6
SDC2 (8q22–q23) rs1042381 108 162 A ⁄T A ⁄A 0 0 1 0.304 0.274 0.037
A ⁄T 21 15 23
T ⁄T 43 48 33
aPositions of the single nucleotide polymorphisms (SNPs) in the respective genes were determined at http://snpper.chip.org.
bPatients in the control group did not show hCMV reactivation. Numbers of homozygous and heterozygous patients used for statistical comparison of the respective patient
groups are speciﬁed.
cAs TLR8 is localised on the X-chromosome, allele frequencies were determined separately according to the gender of the donor.
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In addition, two SNPs localised in the promoter
region of DC-SIGN (rs735240 and rs2287886) were
revealed to be associated signiﬁcantly with hCMV
reactivation or disease. Thus, the G allele of
rs735240 was associated with hCMV reactivation
when compared with the control group (p 0.01,
OR 2.41, 1.22–4.75), and the C allele of rs2287886
was found more frequently in the hCMV disease
group than in the hCMV reactivation group
(p 0.003, OR 2.88, 1.41–5.88). Furthermore, both
markers were associated with hCMV disease
when compared with the control group (p 0.034,
OR 2.01, 1.05–3.86; and p 0.087, OR 1.88,
0.91–3.87, respectively).
In order to determine whether healthy individ-
uals, who have been identiﬁed previously to be
primarily homozygous for CC or TT (rs735240)
and AA or GG (rs2287886), had different levels of
expression of DC-SIGN, expression rates were
analysed on iDCs. It has been demonstrated
previously that acquisition of DC-SIGN is
induced primarily by IL-4 during the monocyte–
DC differentiation pathway [22]. Depending on
the corresponding genotype, iDCs from individ-
uals with the CA haplotype expressed signiﬁ-
cantly higher levels of DC-SIGN in comparison
with individuals with the TG haplotype (Fig. 1;
p 0.04).
Experiments with IE-immunoﬂuorescence
staining showed that iDCs with enhanced expres-
sion of DC-SIGN (CA haplotype) were more
susceptible to infection with the clinically impor-
tant hCMV strain TB40E (29.6 ± 13.9%) than iDCs
generated from individuals with the TG haplo-
type (8.6 ± 5.5%; p 0.037).
By analysing the clinical risk-factors, it was
revealed that acute graft vs. host disease grade
II–IV was associated signiﬁcantly with hCMV
disease (p 0.042). In addition, patients treated
with corticosteroids (>2 mg ⁄ kg body weight)
developed hCMV disease signiﬁcantly more
frequently than patients treated with a lower
dose of steroid (p 0.023). Logistic regression
analysis conﬁrmed the signiﬁcant impact of the
genetic markers on the hCMV group classiﬁca-
tion, whereas the effects of the clinical risk-factors
were negligible. The logistic regression model
revealed no high correlations between markers
and a clinical risk-factor (Table S2, see Supple-
mentary material).
DISCUSSION
This study analysed genetic polymorphisms in
TLR genes and genes encoding PRRs for their
potential association with hCMV reactivation and
disease. It is well-known that different viral patho-
gens, including hCMV, interact with TLRs [7].
However, most previous studies have focused on
an analysis of associations between genetic mark-
ers in TLR2 and TLR4 and bacterial infections [14],
and only limited data exist concerning the associ-
ation of genetic markers in TLR genes with the
occurrence of virus infections. A polymorphism
(rs5743708, Arg753Gln) has been identiﬁed in
TLR2 that is associated with an increased risk of
hCMV disease after liver transplantation [23].
TLR3 and TLR9 have been reported to trigger the
innate immune defence mechanisms against
mouse CMV infection, and TLR9 also appears to
be involved in immune defence against herpes
simplex virus [24,25]. However, the present study
failed to identify any markers in TLR3 and TLR9
that contributed to hCMV susceptibility.
To our knowledge, no data exist concerning an
interaction between TLR8 and hCMV, and it is not
known whether the association of rs3764880 with
hCMV reactivation is coincidental or indicates a
possible role of TLR8 in the innate immune
response to hCMV. Analysis of PRR genes has
revealed an association between the X allele of
rs1042381 (SDC2) and the occurrence of hCMV
disease (as compared to patients with hCMV
reactivation only; p 0.037). As mentioned above,
hCMV interacts with HSPGs during the early
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Fig. 1. Dendritic cell-speciﬁc ICAM3-grabbing non-inte-
grin (DC-SIGN) expression of immature dendritic cells
generated from healthy individuals with different geno-
types. Mean and standard deviations were calculated from
quantitative real-time PCR expression values derived from
ﬁve individuals, each of whom was homozygous for
rs735240 (CC or TT) and rs2287886 (AA or GG; p 0.04).
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stages of infection. Further analysis should
examinewhether the amino-acid substitution from
serine to threonine has an effect on the susceptibil-
ity of host cells to hCMV. The function of DC-SIGN
as a PRR is not fully understood, and this is a
controversial topic [26–28]. DC-SIGN (CD209)
facilitates binding and internalisation of several
viruses (e.g., human immunodeﬁciency virus-1),
bacteria (e.g., Mycobacterium tuberculosis) and par-
asites (e.g., Leishmania and Schistosoma) on DCs.
During the development of human monocyte-
derived DCs, DC-SIGN becomes organised in
well-deﬁned micro-domains on the plasma mem-
brane. This organisation seems to be important for
binding and internalisation of virus particles,
suggesting that these multi-molecular assemblies
of DC-SIGN act as a docking site for pathogens to
invade the host [27]. In contrast, Geijtenbeek et al.
[28] reported that DC-SIGN does not function as a
receptor for viral entry into DCs, but instead
promotes efﬁcient infection in trans of cells that
express CD4 and chemokine receptors.
The present analysis identiﬁed two genetic
markers with signiﬁcant associations: (i)
rs735240, which is associated with hCMV reacti-
vation; and (ii) rs2287886, whose allelic pattern
differed signiﬁcantly between hCMV reactivation
and disease. These results were in agreement with
previous studies of the same gene region. Barreiro
et al. [29] described two promoter variations of
DC-SIGN, at positions )871 (rs735239) and )336
(rs4804803), that were associated with tuberculo-
sis in a South African cohort. Both polymor-
phisms can also be found with a frequent
distribution in a Caucasian population, and are
localised next to rs735240 and rs2287886. In
addition, Sakuntabhai et al. [30] showed that
the )336G allele of rs4804803 was associated
with strong protection against dengue fever, as
opposed to dengue haemorrhagic fever. This
study concluded that the )336A (rs4804803) allele
increases the expression level of DC-SIGN, there-
by probably leading to better capture of patho-
gens and enhanced induction of the adaptive
immune response. Furthermore, Martin et al. [31]
found that Americans of European origin who
were at risk for parenteral human immunodeﬁ-
ciency virus infection were more likely to carry
the )336C SNP than the )336T SNP.
Halary et al. [6] demonstrated that hCMV can
be captured by DCs via binding on DC-SIGN, and
that hCMV envelope glycoprotein B is a viral
ligand for DC-SIGN. The present study revealed
that different DS-SIGN alleles of rs735239 and
rs4804803 inﬂuenced the expression levels of
DC-SIGN. Individuals who were homozygous
for rs735240 (CC) and rs2287886 (AA) showed
signiﬁcantly higher DC-SIGN expression levels
than individuals with TT ⁄GG genotypes (p 0.04).
Furthermore, a signiﬁcantly higher efﬁciency of
infection for DCs with the CA haplotype was
shown than for DCs with the TG haplotype
(p 0.037). To our knowledge, this is the ﬁrst
report of an association between deﬁned poly-
morphisms in DC-SIGN and the amount of
intracellular hCMV IE antigen. These ﬁndings
provide strong evidence of a functional correla-
tion between the deﬁned alleles in DC-SIGN and
hCMV infection efﬁcacy. These results agree with
those of Flint et al. [32], who suggested that
polymorphisms in CD81 (which is a host-cell
receptor for hepatitis C virus) may contribute to
hepatitis C virus susceptibility.
It is unlikely that nucleotide exchanges are the
only cause of hCMV reactivation. Other risk-
factors may also have a causal function. The
higher risk of hCMV reactivation for serologically
positive recipients is undisputed [33], whereas the
inﬂuence of the donor’s serological status on the
outcome is still unclear [34]. In the present
analysis, no association was revealed between
the hCMV status of the donor and hCMV reac-
tivation and disease. However, acute graft vs.
host disease (p 0.042), CD34 selection (p 0.037)
and treatment with corticosteroids (p 0.023) were,
as expected, associated with hCMV disease.
In conclusion, screening of patients for deﬁned
polymorphisms following alloSCT helps to pre-
dict the individual risk of the development of
hCMV reactivation and disease. These genetic
polymorphisms may also inﬂuence the develop-
ment of DC-SIGN-based prophylaxis and therapy
in terms of efﬁciency and safety.
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